Karsten Weller

List of Publications by Year
in descending order

129 papers	6,885 citations	57758 44 h-index	69250 77 g-index
137 all docs	137 docs citations	137 times ranked	3944 citing authors

#	Article	IF	Citations
1	Unmet clinical needs in chronic spontaneous urticaria. A GA2LEN task force report1. Allergy: European Journal of Allergy and Clinical Immunology, 2011, 66, 317-330.	5.7	597
2	Mast cells promote homeostasis by limiting endothelin-1-induced toxicity. Nature, 2004, 432, 512-516.	27.8	275
3	Development and validation of the Urticaria Control Test: AÂpatient-reported outcome instrument for assessing urticaria control. Journal of Allergy and Clinical Immunology, 2014, 133, 1365-1372.e6.	2.9	268
4	Mast cells are required for normal healing of skin wounds in mice. FASEB Journal, 2006, 20, 2366-2368.	0.5	263
5	Autoimmune chronic spontaneous urticaria: What we know and what we do not know. Journal of Allergy and Clinical Immunology, 2017, 139, 1772-1781.e1.	2.9	240
6	Prevalence of chronic urticaria in children and adults across the globe: Systematic review with metaâ€analysis. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 423-432.	5.7	213
7	The burden of chronic spontaneous urticaria is substantial: Realâ€world evidence from <scp>ASSURE</scp>â€<scp>CSU</scp>. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 2005-2016.	5.7	197
8	Development and construct validation of the angioedema quality of life questionnaire. Allergy: European Journal of Allergy and Clinical Immunology, 2012, 67, 1289-1298.	5.7	182
9	Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria. Journal of Allergy and Clinical Immunology, 2017, 139, 1059-1061.e1.	2.9	167
10	The international WAO/EAACI guideline for the management of hereditary angioedemaâ€"The 2021 revision and update. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 1961-1990.	5.7	153
11	European academy of dermatology and venereology European prurigo project: expert consensus on the definition, classification and terminology of chronic prurigo. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 1059-1065.	2.4	150
12	The global burden of chronic urticaria for the patient and society*. British Journal of Dermatology, 2021, 184, 226-236.	1.5	150
13	Development, validation, and initial results of the Angioedema Activity Score. Allergy: European Journal of Allergy and Clinical Immunology, 2013, 68, 1185-1192.	5.7	147
14	Anti-Immunoglobulin E Treatment of Patients with Recalcitrant Physical Urticaria. International Archives of Allergy and Immunology, 2011, 154, 177-180.	2.1	133
15	High Prevalence of Mental Disorders and Emotional Distress in Patients with Chronic Spontaneous Urticaria. Acta Dermato-Venereologica, 2011, 91, 557-561.	1.3	110
16	Efficacy and safety of the interleukinâ€1 antagonist rilonacept in <scp>S</scp>chnitzler syndrome: an openâ€label study. Allergy: European Journal of Allergy and Clinical Immunology, 2012, 67, 943-950.	5.7	110
17	Interleukinâ€31 does not induce immediate itch in atopic dermatitis patients and healthy controls after skin challenge. Allergy: European Journal of Allergy and Clinical Immunology, 2014, 69, 113-117.	5.7	108
18	Urticaria: Collegium Internationale Allergologicum (CIA) Update 2020. International Archives of Allergy and Immunology, 2020, 181, 321-333.	2.1	108

#	Article	IF	Citations
19	Acquired cold urticaria: clinical picture and update on diagnosis and treatment. Clinical and Experimental Dermatology, 2007, 32, 241-245.	1.3	105
20	The Angioedema Quality of Life Questionnaire (<scp>AE</scp>â€QoL) â€“ assessment of sensitivity to change and minimal clinically important difference. Allergy: European Journal of Allergy and Clinical Immunology, 2016, 71, 1203-1209.	5.7	92
21	Omalizumab is effective in cold urticariaâ€"results of a randomized placebo-controlled trial. Journal of Allergy and Clinical Immunology, 2017, 140, 864-867.e5.	2.9	92
22	Efficacy and safety of canakinumab in Schnitzler syndrome: AÂmulticenter randomized placebo-controlled study. Journal of Allergy and Clinical Immunology, 2017, 139, 1311-1320.	2.9	89
23	Chronic spontaneous urticaria in children: Itching for insight. Pediatric Allergy and Immunology, 2011, 22, 1-8.	2.6	87
24	Control of Pseudomonas aeruginosa Skin Infections in Mice Is Mast Cell-Dependent. American Journal of Pathology, 2007, 170, 1910-1916.	3.8	80
25	The Urticaria Activity Scoreâ€"Validity, Reliability, and Responsiveness. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 1185-1190.e1.	3.8	78
26	Angioedema in chronic spontaneous urticaria is underdiagnosed and has a substantial impact: Analyses from <scp>ASSURE</scp>â€<scp>CSU</scp>. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 1724-1734.	5.7	74
27	Total IgE levels are linked to the response of chronic spontaneous urticaria patients to omalizumab. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 2406-2408.	5.7	74
28	Omalizumab is effective in symptomatic dermographismâ€"results of a randomized placebo-controlled trial. Journal of Allergy and Clinical Immunology, 2017, 140, 870-873.e5.	2.9	73
29	Responsiveness and minimal important difference of the urticaria control test. Journal of Allergy and Clinical Immunology, 2017, 140, 1710-1713.e11.	2.9	68
30	Effective treatment of therapy-resistant chronic spontaneous urticaria with omalizumab. Journal of Allergy and Clinical Immunology, 2010, 126, 665-666.	2.9	59
31	Management of chronic spontaneous urticaria in real life â€“ in accordance with the guidelines? A crossâ€sectional physicianâ€based survey study. Journal of the European Academy of Dermatology and Venereology, 2013, 27, 43-50.	2.4	59
32	Lesions on the back of hands and female gender predispose to stigmatization in patients with psoriasis. Journal of the American Academy of Dermatology, 2017, 76, 648-654.e2.	1.2	59
33	Prevalence and clinical characteristics of chronic spontaneous urticaria in pediatric patients. Pediatric Allergy and Immunology, 2018, 29, 630-636.	2.6	57
34	Practical algorithm for diagnosing patients with recurrent wheals or angioedema. Allergy: European Journal of Allergy and Clinical Immunology, 2013, 68, 816-819.	5.7	53
35	German Version of ItchyQoL: Validation and Initial Clinical Findings. Acta Dermato-Venereologica, 2013, 93, 562-568.	1.3	53
36	Efficacy and safety of canakinumab in urticarial vasculitis: An open-label study. Journal of Allergy and Clinical Immunology, 2013, 132, 751-754.e5.	2.9	52

#	Article	IF	Citations
37	Omalizumab rapidly improves angioedemaâ€related quality of life in adult patients with chronic spontaneous urticaria: Xâ€<scp>ACT</scp> study data. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 576-584.	5.7	51
38	Comparison and interpretability of the available urticaria activity scores. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 251-255.	5.7	50
39	Validation of the Angioedema Control Test (AECT)â€"A Patient-Reported Outcome Instrument for Assessing Angioedema Control. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 2050-2057.e4.	3.8	50
40	Results and relevance of critical temperature threshold testing in patients with acquired cold urticaria. British Journal of Dermatology, 2010, 162, 198-200.	1.5	49
41	Symptomatic dermographism: an inadequately described disease. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 708-712.	2.4	48
42	H1-Antihistamine Up-Dosing in Chronic Spontaneous Urticaria: Patients' Perspective of Effectiveness and Side Effects â€“ A Retrospective Survey Study. PLoS ONE, 2011, 6, e23931.	2.5	47
43	Development of the Angioedema Control Testâ€"A patientâ€reported outcome measure that assesses disease control in patients with recurrent angioedema. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 1165-1177.	5.7	47
44	Antihistamineâ€resistant urticaria factitia successfully treated with antiâ€immunoglobulin E therapy. Allergy: European Journal of Allergy and Clinical Immunology, 2010, 65, 1494-1495.	5.7	46
45	Rupatadine improves quality of life in mastocytosis: a randomized, doubleâ€blind, placeboâ€controlled trial. Allergy: European Journal of Allergy and Clinical Immunology, 2013, 68, 949-952.	5.7	46
46	Navigating the landscape of core outcome set development in dermatology. Journal of the American Academy of Dermatology, 2019, 81, 297-305.	1.2	46
47	ASSUREâ€CSU: a realâ€world study of burden of disease in patients with symptomatic chronic spontaneous urticaria. Clinical and Translational Allergy, 2015, 5, 29.	3.2	45
48	Development and validation of the mastocytosis quality of life questionnaire: MC-QoL. Allergy: European Journal of Allergy and Clinical Immunology, 2016, 71, 869-877.	5.7	45
49	Characterization of prodromal symptoms in a large population of patients with hereditary angio-oedema. Clinical and Experimental Dermatology, 2014, 39, 298-303.	1.3	44
50	Can On-demand Non-sedating Antihistamines Improve Urticaria Symptoms? A Double-blind, Randomized, Single-dose Study. Acta Dermato-Venereologica, 2013, 93, 168-174.	1.3	42
51	Report from the kick-off meeting of the Cochrane Skin Group Core Outcome Set Initiative (CSG-COUSIN). British Journal of Dermatology, 2016, 174, 287-295.	1.5	41
52	Antihistamine updosing reduces disease activity in patients with difficult-to-treat cholinergic urticaria. Journal of Allergy and Clinical Immunology, 2016, 138, 1483-1485.e9.	2.9	38
53	The international WAO/EAACI guideline for the management of hereditary angioedema â€“ The 2021 revision and update. World Allergy Organization Journal, 2022, 15, 100627.	3.5	37
54	Turkish Version of the Chronic Urticaria Quality of Life Questionnaire: Cultural Adaptation, Assessment of Reliability and Validity. Acta Dermato-Venereologica, 2012, 92, 419-425.	1.3	36

#	Article	IF	Citations
55	A novel, simple, validated and reproducible instrument for assessing provocation threshold levels in patients with symptomatic dermographism. Clinical and Experimental Dermatology, 2013, 38, 360-366.	1.3	35
56	Disease Activity Only Moderately Correlates with Quality of Life Impairment in Patients with Chronic Spontaneous Urticaria. Dermatology, 2013, 226, 371-379.	2.1	34
57	Clinical Measures of Chronic Urticaria. Immunology and Allergy Clinics of North America, 2017, 37, 35-49.	1.9	34
58	Chronic urticaria: tools to aid the diagnosis and assessment of disease status in daily practice. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 38-44.	2.4	32
59	Pruritus and sleep disturbances in patients with psoriasis. Archives of Dermatological Research, 2020, 312, 103-111.	1.9	32
60	Desloratadine Inhibits Human Skin Mast Cell Activation and Histamine Release. Journal of Investigative Dermatology, 2009, 129, 2723-2726.	0.7	31
61	Development and validation of the Cholinergic Urticaria Qualityâ€ofâ€Life Questionnaire (CholUâ€QoL). Clinical and Experimental Allergy, 2018, 48, 433-444.	2.9	31
62	Selected urticaria patients benefit from a referral to tertiary care centres â€“ results of an expert survey. Journal of the European Academy of Dermatology and Venereology, 2013, 27, e8-16.	2.4	29
63	Core outcome sets in dermatology: report from the second meeting of the International Cochrane Skin Group Core Outcome Set Initiative. British Journal of Dermatology, 2018, 178, e279-e285.	1.5	29
64	Adaptation and initial results of the Polish version of the GA2LEN Chronic Urticaria Quality Of Life Questionnaire (CU-Q2oL). Journal of Dermatological Science, 2011, 62, 36-41.	1.9	28
65	Health-related quality of life with hereditary angioedema following prophylaxis with subcutaneous C1-inhibitor with recombinant hyaluronidase. Allergy and Asthma Proceedings, 2017, 38, 143-151.	2.2	28
66	Management of chronic spontaneous urticaria: a worldwide perspective. World Allergy Organization Journal, 2018, 11, 14.	3.5	28
67	Impact of lanadelumab on healthâ€related quality of life in patients with hereditary angioedema in the HELP study. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 1188-1198.	5.7	28
68	The characteristics and impact of pruritus in adult dermatology patients: A prospective, cross-sectional study. Journal of the American Academy of Dermatology, 2021, 84, 691-700.	1.2	28
69	Clinically relevant outcome measures for assessing disease activity, disease control and quality of life impairment in patients with chronic spontaneous urticaria and recurrent angioedema. Current Opinion in Allergy and Clinical Immunology, 2015, 15, 220-226.	2.3	27
70	Miltefosine Inhibits Human Mast Cell Activation and Mediator Release Both In Vitro and In Vivo. Journal of Investigative Dermatology, 2009, 129, 496-498.	0.7	26
71	Diagnosis and treatment of chronic inducible urticaria. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 2550-2553.	5.7	26
72	Dupilumab in Treatment of Chronic Prurigo: A Case Series and Literature Review. Acta Dermato-Venereologica, 2019, 99, 905-906.	1.3	25

#	Article	IF	Citations
73	Angioedema quality of life questionnaire (AE-QoL) - interpretability and sensitivity to change. Health and Quality of Life Outcomes, 2019, 17, 160.	2.4	24
74	Epidemiology, comorbidities, and healthcare utilization of patients with chronic urticaria in Germany. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 91-99.	2.4	23
75	Chronic Spontaneous Urticaria: How to Assess Quality of Life in Patients Receiving Treatment. Archives of Dermatology, 2011, 147, 1221.	1.4	22
76	AdaptaciÃ³n transcultural del cuestionario Urticaria Control Test del alemÃ¡n al castellano. Actas Dermo-sifiliogrÃ¡ficas, 2015, 106, 746-752.	0.4	22
77	Updosing of bilastine is effective in moderate to severe chronic spontaneous urticaria: A realâ€life study. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 2073-2075.	5.7	22
78	Validation of the Turkish version of the Urticaria Control Test: Correlation with other tools and comparison between spontaneous and inducible chronic urticaria. World Allergy Organization Journal, 2019, 12, 100009.	3.5	22
79	Successful treatment of an acute attack of acquired angioedema with the bradykinin-B2-receptor antagonist icatibant. Journal of the European Academy of Dermatology and Venereology, 2011, 25, 119-120.	2.4	21
80	Validity, reliability and interpretability of the Thai version of the urticaria control test (UCT). Health and Quality of Life Outcomes, 2016, 14, 61.	2.4	21
81	The Diagnostic Workup in Chronic Spontaneous Urticariaâ€”What to Test and Why. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 2274-2283.	3.8	21
82	Chronic Urticaria in Children. JAMA Dermatology, 2017, 153, 1221.	4.1	18
83	Core outcome sets in dermatology: report from the second meeting of the International Cochrane Skin Group Core Outcome Set Initiative. British Journal of Dermatology, 2018, 178, e297-e297.	1.5	18
84	A novel histopathological scoring system to distinguish urticarial vasculitis from chronic spontaneous urticaria. Clinical and Translational Allergy, 2021, 11, e12031.	3.2	18
85	Development and validation of the mastocytosis activity score. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 1489-1496.	5.7	17
86	Lanadelumab Efficacy, Safety, and Injection Interval Extension in HAE: A Real-Life Study. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 3744-3751.	3.8	17
87	Angioedema Activity Score (AAS): A Valid and Reliable Tool to Use in Asian Patients. BioMed Research International, 2019, 2019, 1-4.	1.9	16
88	The Chronic Urticaria Registry: rationale, methods and initial implementation. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 721-729.	2.4	16
89	Knowledge and management of chronic spontaneous urticaria in Latin America: a cross-sectional study in Ecuador. World Allergy Organization Journal, 2017, 10, 21.	3.5	15
90	State of care for patients with systemic autoinflammatory diseases â€“ Results of a tertiary care survey. World Allergy Organization Journal, 2019, 12, 100019.	3.5	15

#	Article	IF	Citations
91	Prevalence and factors associated with sleep disturbance in adult patients with psoriasis. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 688-697.	2.4	15
92	Costâ€intensive, timeâ€consuming, problematical? How physicians in private practice experience the care of urticaria patients. JDDG - Journal of the German Society of Dermatology, 2012, 10, 341-347.	0.8	13
93	The usage, quality and relevance of information and communications technologies in patients with chronic urticaria: A UCARE study. World Allergy Organization Journal, 2020, 13, 100475.	3.5	13
94	Kostenintensiv, zeitaufwendig, problematisch? - Die Betreuung von Urtikariapatienten aus der Perspektive niedergelassener Ã...rzte. JDDG - Journal of the German Society of Dermatology, 2012, 10, 341-349.	0.8	12
95	Cross-Cultural Adaptation of the Urticaria Control Test From German to Castilian Spanish. Actas Dermo-sifiliogrÃ¡ficas, 2015, 106, 746-752.	0.4	12
96	Assessment of disease activity and quality of life in patients with recurrent bradykinin-mediated versus mast cell-mediated angioedema. World Allergy Organization Journal, 2021, 14, 100554.	3.5	12
97	Chronic urticaria in most patients is poorly controlled. Journal of King Abdulaziz University, Islamic Economics, 2017, 38, 1230-1236.	1.1	11
98	How are patients with chronic urticaria interested in using information and communication technologies to guide their healthcare? A UCARE study. World Allergy Organization Journal, 2021, 14, 100542.	3.5	11
99	Miltefosine: a novel treatment option for mast cell-mediated diseases. Journal of Dermatological Treatment, 2013, 24, 244-249.	2.2	10
100	Minimal important difference of the Chronic Urticaria Quality of Life Questionnaire (CUâ€Q2oL). Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 2542-2544.	5.7	10
101	Realâ€life treatment of patients with cholinergic urticaria in Germanâ€speaking countries. JDDG - Journal of the German Society of Dermatology, 2019, 17, 1141-1147.	0.8	10
102	Anxiety and depression seem less common in patients with autoreactive chronic spontaneous urticaria. Clinical and Experimental Dermatology, 2013, 38, 870-873.	1.3	9
103	Rupatadine in Established Treatment Schemes Improves Chronic Spontaneous Urticaria Symptoms and Patientsâ€™ Quality of Life: a Prospective, Non-interventional Trial. Dermatology and Therapy, 2015, 5, 217-230.	3.0	9
104	Subcutaneous self-injections of C1 inhibitor: an effective and safe treatment in a patient with hereditary angio-oedema. Clinical and Experimental Dermatology, 2016, 41, 91-93.	1.3	9
105	The response to treatment in chronic spontaneous urticaria depends on how it is measured. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 2055-2056.e4.	3.8	9
106	Sleep disturbance in adult dermatologic patients: A cross-sectional study on prevalence, burden, and associated factors. Journal of the American Academy of Dermatology, 2021, 85, 910-922.	1.2	9
107	Chronic urticaria patients are interested in apps to monitor their disease activity and control: A UCARE CURICT analysis. Clinical and Translational Allergy, 2021, 11, e12089.	3.2	9
108	Automatic screening of selfâ€evaluation apps for urticaria and angioedema shows a high unmet need. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 3810-3813.	5.7	8

#	Article	IF	Citations
109	A comprehensive, triâ€national, crossâ€sectional analysis of characteristics and impact of pruritus in psoriasis. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 2064-2075.	2.4	8
110	Comparison of pruritus and sensory qualities induced by capsaicin, histamine and cowhage. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 1755-1761.	2.4	7
111	How to Measure Disease Activity, Impact, and Control in Patients with Recurrent Wheals, Angioedema, or Both. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 2151-2157.	3.8	7
112	Off-label prescriptions and decisions on reimbursement requests in Germany - a retrospective analysis. JDDG - Journal of the German Society of Dermatology, 2017, 15, 1103-1109.	0.8	6
113	Reply. Journal of Allergy and Clinical Immunology, 2018, 141, 1166-1167.	2.9	6
114	Chronic spontaneous urticaria activity, impact and control as well as their changes are strongly linked, and these links are not affected by angioedema or comorbid inducible urticaria â€“ Results from the validation of the Polish Urticaria Control Test. World Allergy Organization Journal, 2022, 15, 100635.	3.5	6
115	Patient-reported Outcome Measures for Angioedema: A Literature Review. Acta Dermato-Venereologica, 2021, 101, adv00456.	1.3	5
116	Development of the Cold Urticaria Activity Score. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 2509-2519.	5.7	5
117	Impaired Tâ€cellâ€dependent protection against <scp>L</scp>eishmania major infection in <scp>HIV</scp>â€positive patients is associated with worsened disease outcome. Experimental Dermatology, 2015, 24, 302-304.	2.9	4
118	The Arabic Urticaria Activity Score and Chronic Urticaria Quality of Life Questionnaire: validation and correlations. International Journal of Dermatology, 2020, 59, 893-901.	1.0	4
119	Validity, reliability, and interpretability of the Brazilian urticaria control test. Allergy and Asthma Proceedings, 2020, 41, e61-e66.	2.2	4
120	Atopic dermatitis and allergic rhinitis â€“ do coâ€effects in therapy exist?. JDDG - Journal of the German Society of Dermatology, 2012, 10, 221-239.	0.8	3
121	Antihistamine updosing in chronic urticaria - is there enough evidence?. British Journal of Dermatology, 2016, 175, 1134-1135.	1.5	3
122	Off-Label-Use und Entscheidungen Ã¼ber AntrÃge auf KostenÃ¼bernahme in Deutschland - eine retrospektive Analyse. JDDG - Journal of the German Society of Dermatology, 2017, 15, 1103-1110.	0.8	3
123	Flare Size but Not Intensity Reflects Histamine-Induced Itch. Skin Pharmacology and Physiology, 2020, 33, 244-252.	2.5	3
124	Heat urticaria - easy to diagnose but also to misdiagnose. British Journal of Dermatology, 2016, 175, 454-455.	1.5	2
125	Reply to Ensina et al. Pediatric Allergy and Immunology, 2018, 29, 670-671.	2.6	1
126	Impact of Chronic Urticaria and How to Measure It. , 2021, , 39-56.		1

#	Article	IF	Citations
127	Disease Impact, Diagnostic Delay, and Unmet Medical Needs of Patients With Cholinergic Urticaria in German-Speaking Countries. Frontiers in Allergy, 2022, 3, .	2.8	1
128	Assessment of urticaria using a selfâ€reported diagnosis tool (SRUD): a multicentre validation study. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e652-e654.	2.4	0
129	Evaluation of the Reliability and Validity of the Persian Version of Urticaria Control Test (UCT). Iranian Journal of Allergy, Asthma and Immunology, 2021, 20, 423-431.	0.4	0